STOCK TITAN

Phoenix Asia terminates ACEA Pharma acquisition

The proposed exchange of 100,000,000 newly issued ordinary shares for ACEA Pharma’s equity will not be completed.

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(Moderate)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
6-K

Rhea-AI Filing Summary

Phoenix Asia Holdings Ltd terminated its Stock Acquisition Agreement with ACEA Therapeutics, Inc., under which it would have acquired all of ACEA Pharma, Inc. for 100,000,000 newly issued ordinary shares. Closing had not occurred by November 2, 2026, the agreement’s Outside Date; Phoenix Asia delivered written termination notice on November 3, 2026, effective that date. Closing had been subject to customary conditions, including regulatory approvals.

As of November 9, 2026, no shares had been issued to ACEA Therapeutics, no ACEA Pharma equity interests had transferred, and Phoenix Asia had paid no acquisition consideration. The agreement provides for no termination fee and, except as otherwise provided, each party bears its own costs and expenses.

Filing Explained

Although the acquisition agreement is terminated, the termination does not release either party from liability that arose before termination; Articles XI, XII and XIII also survive, and Phoenix Asia reserves its rights and remedies under the agreement and applicable law.

Proposed acquisition consideration 100,000,000 newly issued ordinary shares Exchange for all issued and outstanding equity interests of ACEA Pharma, Inc.
Outside Date November 2, 2026 Closing had not occurred on or before this date.
Termination effective date November 3, 2026 Date Phoenix Asia delivered written termination notice.
Outside Date technical
"after November 2, 2026 (the “Outside Date”)"
An outside date is the final contractual deadline by which a planned deal—such as a merger, acquisition, or financing—must be completed; if the transaction hasn’t closed by that date, parties typically gain the right to walk away or trigger agreed remedies. It matters to investors because it sets a clear timetable for when uncertainty should end, and approaching or missing the outside date can raise the chance of deal failure, renegotiation, or changes to valuation.
termination fee financial
"does not provide for a termination fee"
A termination fee is a payment required if one party ends a contract before its agreed-upon end date. It acts like a penalty or compensation to the other party for canceling early, similar to a fee you might pay for breaking a lease or canceling a service contract. For investors, it matters because it can influence a company's decisions and financial obligations related to ending agreements prematurely.
Hart-Scott-Rodino Antitrust Improvements Act regulatory
"waiting periods under the Hart-Scott-Rodino Antitrust Improvements Act of 1976"
A U.S. law that requires companies planning large mergers or acquisitions to notify federal antitrust authorities and wait for review before completing the deal. Think of it like applying for a building permit: regulators check whether the combined business would unfairly hurt competition and can clear the deal, impose changes, or seek to stop it, so the process affects transaction timing, cost, and whether expected benefits reach investors.
exclusive jurisdiction regulatory
"exclusive jurisdiction of the state and federal courts sitting in New York, New York"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

Why did PHOE terminate its ACEA Pharma acquisition agreement?

Closing had not occurred by November 2, 2026, the agreement’s Outside Date. Phoenix Asia Holdings Ltd delivered written notice to ACEA Therapeutics, Inc. on November 3, 2026, terminating the agreement effective that date.

Does PHOE’s terminated acquisition agreement include a termination fee?

The agreement does not provide for a termination fee. Except as otherwise provided in the agreement, each party bears its own costs and expenses.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

FORM 6-K

 

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

 

For the month of November 2026

 

Commission File Number: 001-42618

 

Phoenix Asia Holdings Limited

(Registrant’s Name)

 

Workshop B14, 8/F, Block B, Tonic Industrial Center, 19 Lam Hing Street, Kowloon Bay, Hong Kong

(Address of Principal Executive Offices)

 

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

 

Form 20-F ☒ Form 40-F ☐

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐

 

 

 

 
 

 

Termination of Stock Acquisition Agreement

 

As previously reported in the Report on Form 6-K furnished by Phoenix Asia Holdings Limited (the “Company”) on May 4, 2026, the Company entered into a Stock Acquisition Agreement dated May 4, 2026 (the “Stock Acquisition Agreement”) with ACEA Pharma, Inc. (the “Target Company”) and ACEA Therapeutics, Inc. (the “Transferor”). Under the Stock Acquisition Agreement, the Company would have acquired all of the issued and outstanding equity interests of the Target Company in exchange for 100,000,000 newly issued ordinary shares of the Company. Closing was subject to customary conditions and regulatory approvals, including the expiration or termination of waiting periods under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, and the receipt of any required approval from The Nasdaq Stock Market LLC (“Nasdaq”).

 

Section 11.1(b) of the Stock Acquisition Agreement permits either the Company or the Transferor to terminate the agreement after November 2, 2026 (the “Outside Date”), if closing has not occurred on or before the Outside Date and the terminating party has not materially breached the agreement, subject to the provisos in that section. Closing did not occur on or before the Outside Date. On November 3, 2026, the Company delivered written notice to the Transferor terminating the Stock Acquisition Agreement pursuant to Section 11.1(b), effective as of the date of the notice. The Company believes it has not materially breached any provision of the Stock Acquisition Agreement in a manner that would preclude it from exercising this termination right. As a result, the transactions contemplated by the Stock Acquisition Agreement will not be consummated. The Company has expressly reserved all of its rights and remedies under the Stock Acquisition Agreement, applicable law and otherwise.

 

Under Section 11.2 of the Stock Acquisition Agreement, following a valid termination, the rights and obligations of the parties terminate and are of no further force or effect, except that Articles XI, XII and XIII survive, and no party is released from any liability to another party that arose under the Stock Acquisition Agreement before termination. The surviving provisions include New York governing law, exclusive jurisdiction of the state and federal courts sitting in New York, New York, and a waiver of jury trial. The Stock Acquisition Agreement does not provide for a termination fee and, except as otherwise provided therein, each party bears its own costs and expenses. As of the date of this report, no ordinary shares of the Company have been issued to the Transferor, no equity interests of the Target Company have been transferred to the Company, and no acquisition consideration has been paid by the Company under the Stock Acquisition Agreement.

 

Incorporation by Reference

 

This Report on Form 6-K is hereby incorporated by reference into the Company’s registration statement on Form S-8 (Registration Number 333-291901) and into each prospectus outstanding under that registration statement, to be a part thereof from the date on which this report is furnished, to the extent not superseded by documents or reports subsequently filed or furnished.

 

Forward-Looking Statements

 

This Report on Form 6-K contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements are intended to be covered by the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements regarding the expected effects of the termination of the Stock Acquisition Agreement and the outcome of any disputes or claims arising in connection with the termination. Words such as “anticipate,” “believe,” “expect,” “intend,” “may,” “plan,” “will” and similar expressions identify forward-looking statements. These statements are not guarantees of future performance and involve risks and uncertainties that could cause actual results to differ materially. Such risks include the risk that the Transferor or the Target Company disputes the termination or commences litigation, the costs and outcome of any proceeding, the effect of the termination on the Company’s share price and business, and the risks discussed under “Risk Factors” in the Company’s Annual Report on Form 20-F for the fiscal year ended March 31, 2026. Forward-looking statements speak only as of the date of this report. Except as required by applicable law, the Company undertakes no obligation to update any forward-looking statement.

 

 
 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

  Phoenix Asia Holdings Limited
     
Date: November 9, 2026 By: /s/ Chi Kin Kelvin Yeung
  Name: Chi Kin Kelvin Yeung
  Title: Chief Executive Officer

 

 

 

 

Keep reading